Table 2.
Author (year) | Study Design, Blinded (duration) | Population | Intervention (number of surgical sites) | |||
---|---|---|---|---|---|---|
No. of participants (sites) | Age (mean/range) | gender | Control (sites) | Test (sites) | ||
Bozkurt et al. (2015) [29] | Split-mouth, examiner-blinded (6 months) | 20 (119) | 37.1 ± 1.03 (20–45) | 7 M/13F | CAF (59) | CAF + CGF (60) |
Akcan et al. (2020) [55] | Split-mouth, N (6 months) | 19 (74) | N (20–63) | 11 M/8F | CAF + CTG (37) | CAF + CGF (37) |
Korkmaz et al. (2021) [59] | Parallel, examiner-blinded (6 months) | 40 (108) | 41.1 ± 9.3 (26–63) | N | TT + CTG (51) | TT + CGF (57) |
Xue et al. (2022) [67] | Parallel, N (6 months) | 28 (70) | 38.56 ± 9.28 (N) | 17 M/11F | CAT + CTG (34) | CAT + CGF (36) |
Öngöz et al. (2023) [46] | Parallel, examiner-blinded (6 months) | 16 (45) | 35.31 ± 5.55 (25–45) | 8 M/8F | CAF (15) | T1: CAF + CGF (15); T2: CAF + PRF (15) |
CAF: coronally advanced flap; CTG: connective tissue graft; CGF: concentrated growth factor; TT: tunnel technique; N: not mentioned